What Windward Bio does

Windward Bio AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland, founded in January 2025 to develop long-acting biologics for serious immunological diseases. Its pipeline is anchored by WIN378, a next-generation fully human anti-TSLP monoclonal antibody engineered for half-life extension and silenced effector function to enable twice-yearly subcutaneous dosing; WIN378 is being evaluated in the POLARIS Phase 2/3 study in severe asthma (with initial readouts expected in H2 2026 and Phase 3 initiation planned for Q4 2026) and in the SIRIUS Phase 2 study in COPD (first patients dosed June 2026). The portfolio was extended in December 2025 with WIN027, a long-acting anti-TSLPxIL-13 bispecific antibody currently in Phase 1, in-licensed from Qyuns Therapeutics in a deal valued at up to $700 million in milestones and royalties and targeted at respiratory and dermatological indications.

The company's underlying technology is a protein-engineering platform focused on half-life extension (HLE) and effector-function silencing, applied to monoclonal and bispecific antibodies against clinically validated immunology targets (TSLP, IL-13). WIN378 was licensed from Kelun-Biotech (SKB378) and Harbour BioMed (HBM9378); WIN027 was licensed from Qyuns Therapeutics. Global development and commercialization rights are held ex-Greater China and select Southeast/West Asian territories for WIN378 and ex-China for WIN027. Phase 1 data for WIN378 demonstrated a mean half-life of 55-65.8 days across dose cohorts (20-900 mg), a low rate of antidrug antibodies, and a favorable safety profile.

Windward Bio is pre-revenue with no marketed products; the expected revenue mechanics are product sales or licensing income from approved biologics in respiratory and dermatology, with eventual commercialization likely through pharmaceutical partnerships or specialty field sales targeting respiratory and immunology specialists. The company has raised $365 million to date from a syndicate led by OrbiMed (lead in both rounds) and including Novo Holdings, Blue Owl, SR One, Omega Funds, RTW, Qiming, Quan, Pivotal, RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed.

Name

Windward Bio

Legal name

Windward Bio AG

Website

https://windwardbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Windward Bio is a clinical-stage Swiss biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological diseases, with lead program WIN378 (anti-TSLP) in Phase 2/3 for asthma and Phase 2 for COPD.

Ownership category

akta.pro rank

Product category

Immunology Biologics

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Clinical-stage biotechnology
• Monoclonal antibody therapy
• Immunology biologics
• Respiratory drug development
• Long-acting therapeutics

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pipeline Development (Pre-Revenue): Windward Bio is a clinical-stage company with no marketed products. The company is developing WIN378 (anti-TSLP mAb) and WIN027 (anti-TSLPxIL-13 bispecific) through clinical development toward commercialization. Revenue will ultimately derive from product sales or licensing of approved biologics in respiratory and dermatological conditions.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibody therapeutics for serious immunological diseases. Its lead product, WIN378, is a half-life-extended anti-TSLP monoclonal antibody in Phase 2/3 for asthma and Phase 2 for COPD, designed for twice-yearly subcutaneous dosing. The pipeline also includes WIN027, a long-acting anti-TSLPxIL-13 bispecific antibody in Phase 1 for respiratory and dermatological conditions.

Product overview

Windward Bio is a clinical-stage biotechnology company developing a portfolio of long-acting biologics targeting immunological diseases. The company's lead program WIN378 is an anti-TSLP monoclonal antibody in Phase 2/3 for asthma and Phase 2 for COPD, designed for twice-yearly subcutaneous dosing. The pipeline also includes WIN027, a clinical-stage bispecific antibody targeting both TSLP and IL-13, currently in Phase 1 for respiratory and dermatological conditions. The company is building a discovery pipeline of additional long-acting bispecific antibodies targeting validated biology in respiratory and dermatological diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• WIN378 WIN378 is a next-generation, fully human anti-TSLP monoclonal antibody engineered for half-life extension and silenced effector function, developed for twice-yearly subcutaneous dosing in severe asthma and COPD. It is being evaluated in the POLARIS Phase 2/3 asthma trial and the SIRIUS Phase 2 COPD trial.
• WIN027 WIN027 is a long-acting anti-TSLPxIL-13 bispecific antibody targeting two validated pathways in immunological diseases, currently in Phase 1 clinical development for respiratory and dermatological indications.

Quantifiable outcome

• WIN378 Phase 1 demonstrated mean half-life of 55-65.8 days, supporting twice-yearly subcutaneous dosing potential
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Kelun-BiotechcoreOEM/ Whitelabel/ Licensing PartnerWindward Bio licensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 (anti-TSLP mAb, also known as SKB378) from Kelun-Biotech. Kelun-Biotech is a Chinese biopharmaceutical company that developed the antibody and retains rights in its home territory. WIN378 is Windward Bio's lead program in Phase 2/3 for asthma and Phase 2 for COPD.
• Harbour BioMedcoreOEM/ Whitelabel/ Licensing PartnerWindward Bio co-licensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 (also known as HBM9378) from Harbour BioMed alongside Kelun-Biotech. Harbour BioMed is a global biopharmaceutical company with expertise in antibody therapeutics. Phase 1 results for WIN378 were published in Drug Design, Development and Therapy.
• Qyuns TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerWindward Bio entered a licensing agreement with Qyuns Therapeutics for WIN027, a long-acting bispecific antibody targeting TSLP and IL-13, currently in Phase 1. The deal grants Windward Bio exclusive development, manufacturing, and commercialization rights outside of China, valued at up to $700 million including milestone payments and royalties. This was the company's second China deal in 2024.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Upstream Bio: Clinical-stage biotech developing verekitug, an anti-TSLP receptor monoclonal antibody for severe asthma and other respiratory diseases. Most direct anti-TSLP competitor to WIN378 in clinical development.
• Verona Pharma: Late clinical-stage respiratory biotech developing ensifentrine for COPD. Directly comparable as a clinical-stage company focused on serious respiratory disease and a candidate strategic combination for Windward's COPD program.
• AnaptysBio: Clinical-stage immunology antibody developer with wholly-owned antibodies in inflammatory/immunological indications. Comparable business model as a focused antibody developer targeting validated immunology pathways.
• Theravance Biopharma: Clinical-stage respiratory-focused biotech with late-stage programs in COPD and asthma. Comparable as a similarly sized immunology/respiratory specialist pursuing biologics in overlapping indications.

Broad incumbents

• Sanofi: Partner with Regeneron on Dupixent and a current Windward Bio investor via Sanofi Ventures. Represents both a competitive threat (Dupixent) and a likely strategic-acquirer/partner candidate for WIN378/WIN027.
• AstraZeneca: Co-developer with Amgen of Tezspire (tezepelumab), the only approved anti-TSLP antibody for severe asthma. A direct competitor to WIN378 and a benchmark for the TSLP category.
• Regeneron Pharmaceuticals: Co-developer with Sanofi of Dupixent (dupilumab), the leading anti-IL-4/IL-13 biologic in asthma and atopic dermatitis. Sets the efficacy/safety benchmark that WIN027 (TSLPxIL-13) must compete against.

Others

• Harbour BioMed: Co-licensor of WIN378 to Windward Bio and a current investor. An antibody-focused biopharma whose portfolio and discovery platform overlap with Windward's mechanism area.
• Qyuns Therapeutics: Original developer and licensor of WIN027 (TSLPxIL-13 bispecific) to Windward Bio in a deal worth up to $700M. Comparable as a Chinese clinical-stage antibody specialist with retained China rights to a shared asset.
• Kelun-Biotech: Original developer and licensor of WIN378 (anti-TSLP mAb, SKB378) to Windward Bio. Comparable as a clinical-stage antibody developer with retained China rights to the same molecule.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Windward Bio